AVTX - Company ID 0001534120
Avalo Therapeutics, Inc. trades as AVTX. In its fiscal 2025 annual report the company posted revenue of $59.00K, down 86.6% from the prior year and net income of -$78.26M. This page tracks Avalo Therapeutics, Inc. through 997 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Avalo Therapeutics, Inc.'s revenue declined from $1.15M to $59.00K, a compound annual decline rate of 28.1%. Net profit margin compressed from -1428.6% to -132642.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| SCHEDULE 13G | - | 2026-05-26 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-15 |
The largest companies sharing Avalo Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Avalo Therapeutics, Inc. reported revenue of $59.00K for fiscal year 2025, a decrease of 86.6% year over year.
In its latest fiscal year Avalo Therapeutics, Inc. reported a net loss of $78.26M.